New first-in-class drug for the treatment of ER+ MBC
Article by Dr. Angela Alexander On Apr 30th, the FDA approved a new first-in-class drug for the treatment of ER+ metastatic breast cancer (MBC). The new drug Vepdegestrant was approved only for patients with tumors that harbor ESR1 mutations, based on results from...
It Hardly Mattered
What we don’t know — and why it matters by Terry Arnold On a flight to Cleveland, the woman beside me leaned back in her seat and said in a mocking voice, “She waited too long.” It took every ounce of self-control I had. After about an hour of silence, we had started...
IBC Network Foundation at the 2025 San Antonio Breast Cancer Symposium
Co authors: Terry Arnold and Stephanie Pilkinton Every December, the global breast cancer community gathers in San Antonio, Texas, for the San Antonio Breast Cancer Symposium (SABCS) — the largest breast cancer research meeting in the world. For those of us focused on...